Advances in the use of biologic agents for the treatment of systemic vasculitis

Sharon A. Chung; Philip Seo

doi:10.1097/BOR.0b013e32831d28b3

Advances in the use of biologic agents for the treatment of systemic vasculitis

Sharon A. Chung, Philip Seo

Research output: Contribution to journal › Review article › peer-review

22 Scopus citations

Abstract

Biologic agents represent the next evolution in treatment for the primary systemic vasculitides. Greater understanding of these diseases has allowed us to move further away from nonspecific, highly toxic therapies toward a more directed approach. As our experience with these agents increases, they will likely form the keystone of treatment in the near future.

Original language	English (US)
Pages (from-to)	3-9
Number of pages	7
Journal	Current opinion in rheumatology
Volume	21
Issue number	1
DOIs	https://doi.org/10.1097/BOR.0b013e32831d28b3
State	Published - Jan 2009
Externally published	Yes

Keywords

Anti-TNF
Intravenous immunoglobulin
Rituximab
Vasculitis

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1097/BOR.0b013e32831d28b3

Cite this

@article{9befc092877a41e3a7232960f5ef8235,

title = "Advances in the use of biologic agents for the treatment of systemic vasculitis",

abstract = "Biologic agents represent the next evolution in treatment for the primary systemic vasculitides. Greater understanding of these diseases has allowed us to move further away from nonspecific, highly toxic therapies toward a more directed approach. As our experience with these agents increases, they will likely form the keystone of treatment in the near future.",

keywords = "Anti-TNF, Intravenous immunoglobulin, Rituximab, Vasculitis",

author = "Chung, {Sharon A.} and Philip Seo",

year = "2009",

month = jan,

doi = "10.1097/BOR.0b013e32831d28b3",

language = "English (US)",

volume = "21",

pages = "3--9",

journal = "Current opinion in rheumatology",

issn = "1040-8711",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Advances in the use of biologic agents for the treatment of systemic vasculitis

AU - Chung, Sharon A.

AU - Seo, Philip

PY - 2009/1

Y1 - 2009/1

N2 - Biologic agents represent the next evolution in treatment for the primary systemic vasculitides. Greater understanding of these diseases has allowed us to move further away from nonspecific, highly toxic therapies toward a more directed approach. As our experience with these agents increases, they will likely form the keystone of treatment in the near future.

AB - Biologic agents represent the next evolution in treatment for the primary systemic vasculitides. Greater understanding of these diseases has allowed us to move further away from nonspecific, highly toxic therapies toward a more directed approach. As our experience with these agents increases, they will likely form the keystone of treatment in the near future.

KW - Anti-TNF

KW - Intravenous immunoglobulin

KW - Rituximab

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=58149269251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149269251&partnerID=8YFLogxK

U2 - 10.1097/BOR.0b013e32831d28b3

DO - 10.1097/BOR.0b013e32831d28b3

M3 - Review article

C2 - 19077713

AN - SCOPUS:58149269251

SN - 1040-8711

VL - 21

SP - 3

EP - 9

JO - Current opinion in rheumatology

JF - Current opinion in rheumatology

IS - 1

ER -

Advances in the use of biologic agents for the treatment of systemic vasculitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this